Legend Biotech to Participate in the 41st Annual JP Morgan Healthcare Conference
January 03 2023 - 4:01PM
Business Wire
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a
global biotechnology company developing, manufacturing and
commercializing novel therapies to treat life-threatening diseases
today announced its participation in the 41st annual JP Morgan
Healthcare Conference in San Francisco, CA.
CEO Ying Huang, PhD will deliver the company presentation on
Tuesday, January 10, 2023 at 2:15 pm (Pacific Time).
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to
treating, and one day curing, life-threatening diseases.
Headquartered in Somerset, New Jersey, we are developing advanced
cell therapies across a diverse array of technology platforms,
including autologous and allogeneic chimeric antigen receptor
T-cell and natural killer (NK) cell-based immunotherapy. From our
three R&D sites around the world, we apply these innovative
technologies to pursue the discovery of cutting-edge therapeutics
for patients worldwide.
Learn more at www.legendbiotech.com and follow us on Twitter and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230103005568/en/
Investor Contacts: Joanne Choi, Senior Manager, Investor
Relations, Legend Biotech joanne.choi@legendbiotech.com
Crystal Chen, Manager, Investor Relations, Legend Biotech
crystal.chen@legendbiotech.com
Press Contact: Tina Carter, Corporate Communications
Lead, Legend Biotech tina.carter@legendbiotech.com (908)
331-5025
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart
From Sep 2023 to Sep 2024